A Novel System for the Quantification of the ADCC Activity of Therapeutic Antibodies

Figure 10

Comparison of the ADCC activity of WT, ERBB2⁺, and ERBB2⁻ HEK293 cells. iLite effector cells (1.2 × 10⁵ cells/well) were mixed with 3 × 10⁴ WT, ERBB2⁺, or ERBB⁻ target cells for 6 hours in the presence of increasing concentrations of trastuzumab prior to the addition of Nano-Glo Dual-luciferase reagent (Promega, Madison, WI) and the sequential determination of FL and NL activity. Results are expressed as RLU (a) or fold induction (b).